Big Pharma Split Corp.
PRM.TO
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 784.09% | 799.05% | -76.46% | -77.04% | -110.51% |
| Total Revenue | 784.09% | 799.05% | -76.46% | -77.04% | -110.51% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 784.09% | 799.05% | -76.46% | -77.04% | -110.51% |
| SG&A Expenses | 5.85% | 8.25% | -21.33% | -23.29% | -14.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 12.33% | 14.68% | -7.07% | -9.90% | -61.65% |
| Total Operating Expenses | 6.99% | 9.39% | -19.74% | -21.74% | -29.66% |
| Operating Income | 423.06% | 430.20% | -85.89% | -86.24% | -122.12% |
| Income Before Tax | 314.54% | 319.22% | -123.58% | -122.97% | -126.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 314.54% | 319.22% | -123.58% | -122.97% | -126.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 314.54% | 319.22% | -123.58% | -122.97% | -126.17% |
| EBIT | 423.06% | 430.20% | -85.89% | -86.24% | -122.12% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 330.44% | 335.46% | -130.06% | -129.27% | -131.59% |
| Normalized Basic EPS | 330.34% | 335.62% | -130.02% | -129.25% | -131.61% |
| EPS Diluted | 330.44% | 335.46% | -130.06% | -129.27% | -131.59% |
| Normalized Diluted EPS | 330.34% | 335.62% | -130.02% | -129.25% | -131.61% |
| Average Basic Shares Outstanding | -6.91% | -6.91% | -21.61% | -21.61% | -17.14% |
| Average Diluted Shares Outstanding | -6.91% | -6.91% | -21.61% | -21.61% | -17.14% |
| Dividend Per Share | -1.82% | 0.31% | -0.26% | -2.74% | -4.99% |
| Payout Ratio | 1.43% | 1.43% | -4.19% | -4.19% | -4.12% |
